O/N Nasdaq, page-587

Lots happening behind the scenes. "Flash note" update from Goetz Partners...

'key areas of focus at investor meetings they hosted
in London and further take the opportunity to flag the clinical trial collaboration
and supply agreement Immutep signed with Merck KGaA / Pfizer focused on
evaluating anti-PD-L1 Bavencio (avelumab) with Immutep's lead asset eftilagimod
alpha ("efti"). 2019 will be a decisive year rich in pipeline events and we see room
for significant upside from our conservative AUD0.078 target price. The company
is burning c.AUD10m / year and is fully funded until YE2019E in the absence of
income from a potential licensing deal. We maintain and reiterate our OUTPERFORM​

recommendation." Immutep web site - 'whats new'

Long termers: Between October - July 2019 - a mere 8 months max we will know.....

	Column 1
0	TACTI-meldata from fourth patient cohort (30 mg dose at cycle 1): H22018
1	TACTI-002 to commence, Phase II trial in collaboration with MSD: H22018
2	IMP761 preclinical data: 2018
3	INSIGHT single cases from study: throughout 2018
4	AIPAC final progression free survival data (metastatic breast cancer trial): H12019